R&D News | pharmaphorum

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

News

ESMO: Pfizer drug helps cancer patients gain weight

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no a

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

Trial sets up filings for Boehringer IPF drug nerandomilast

ESMO: Pfizer drug helps cancer patients gain weight

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

ESMO: Incyte's PD-1 treads new ground in anal cancer

ESMO: GSK, iTeos bring some optimism back to TIGIT

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks